Chronic Stress-Triggerable Nanoprodrugs Ameliorate Metabolic Abnormalities Driven by Hypothalamic-Pituitary-Adrenal Axis Dysregulation in Early Alzheimer’s Disease
ACS Nano · 12.11.2026
DOI: 10.1021/acsnano.6c14806 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 12.11.2026. Verfasst von Xiaomeng Yu und 7 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Tianjin Municipal Health Commission, National Natural Science Foundation of China, Tianjin Municipal Education Commission.
Themen: Demenz
Abstract (Originalsprache)
Chronic stress-induced dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is a crucial early risk factor that triggers brain energy metabolism disorders to accelerate the onset and progression of Alzheimer’s disease (AD). Herein, an amphiphilic precursor conjugate of ginsenoside Rc (Rc) covalently linked with a reactive oxygen species-sensitive thioketo bond is constructed to form stimuli-responsive prodrug assemblies, which are further modified with the TGN-Tet1 dual-ligand fusion peptide TPL to obtain a chronic stress-triggerable programmed nanoprodrug (TLRN). Following TPL-mediated blood-brain barrier penetration and neuronal preferential targeting, nanoprodrugs specifically disintegrate to selectively release active Rc in the chronic stress-induced excessive reactive oxygen species (ROS) microenvironment. Benefiting from the restoration of HPA axis homeostasis by normalizing glucocorticoid receptor nuclear translocation, TLRN treatment exhibits multifaceted rectification of cerebral metabolic abnormalities, including enhancing glucose uptake, promoting oxidative phosphorylation, and mitigating mitochondrial dysfunction. In young amyloid precursor protein/presenilin 1 (APP/PS1) transgenic mouse models exposed to chronic stress, this intervention can alleviate brain energy deprivation and amyloid-β (Aβ) accumulation, ultimately rescuing depressive-like behaviors and cognitive deficits, offering a promising approach for early prevention and flexible management of AD at high risk of chronic stress.
Förderung
- Tianjin Municipal Health Commission
- National Natural Science Foundation of China
- Tianjin Municipal Education Commission
Zitieren
APA
Yu, X., Yang, F., Liu, Y., Xie, J., Xie, J., Chen, Y., Chang, J., & Dou, Y. (2026). Chronic Stress-Triggerable Nanoprodrugs Ameliorate Metabolic Abnormalities Driven by Hypothalamic-Pituitary-Adrenal Axis Dysregulation in Early Alzheimer’s Disease. ACS Nano. https://doi.org/10.1021/acsnano.6c14806
Vancouver
Yu X, Yang F, Liu Y, Xie J, Xie J, Chen Y, et al. Chronic Stress-Triggerable Nanoprodrugs Ameliorate Metabolic Abnormalities Driven by Hypothalamic-Pituitary-Adrenal Axis Dysregulation in Early Alzheimer’s Disease. ACS Nano. 2026. doi:10.1021/acsnano.6c14806
BibTeX
@article{Yu2026,
author = {Yu, Xiaomeng and Yang, Fan and Liu, Yining and Xie, Jiyao and Xie, Jiamei and Chen, Yihan and Chang, Jin and Dou, Yan},
title = {Chronic Stress-Triggerable Nanoprodrugs Ameliorate Metabolic Abnormalities Driven by Hypothalamic-Pituitary-Adrenal Axis Dysregulation in Early Alzheimer’s Disease},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.6c14806}
}
EUVIMED